Published in Onco Targets Ther on October 14, 2016
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int (1994) 2.42
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol (2015) 1.81
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet (2014) 1.66
Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol (2000) 1.53
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res (2009) 1.42
Thymic neuroendocrine carcinoma and thymoma are both associated with increased risk of extrathymic malignancy: a 20-year review of a single institution. Ann Thorac Surg (2011) 1.41
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol (2014) 1.40
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer (2010) 1.23
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer (2008) 1.21
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med (2004) 1.19
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol (2009) 1.07
Management of thymic tumors-consensus based on the Chinese Alliance for Research in Thymomas Multi-institutional retrospective studies. J Thorac Dis (2016) 0.98
Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur J Cardiothorac Surg (2015) 0.97
Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol (2006) 0.97
Thymoma and multiple malignancies: a case of five synchronous neoplasms and literature review. Clin Med Res (2003) 0.95
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget (2015) 0.90
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget (2013) 0.89
Thymic carcinoma patients with myasthenia gravis exhibit better prognoses. Int J Clin Oncol (2015) 0.84
Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004. J Thorac Dis (2016) 0.83
Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database. Ann Surg Oncol (2016) 0.82
Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology (2003) 0.81
Genetic profiling of thymic carcinoma using targeted next-generation sequencing. Lung Cancer (2014) 0.80
Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. J Thorac Oncol (2010) 0.77